论文部分内容阅读
目的:评估国产西罗莫司药物洗脱支架Firebird2TM治疗急性心肌梗死的安全性和有效性。方法:连续入选2010年9月至2011年12月因急性心肌梗死在我院行介入治疗的120例患者。观察并分析所有患者冠状动脉的靶血管特点、支架植入情况、住院期间和支架植入术后6个月的主要心脏不良事件(MACE,包括死亡、再发心梗、靶血管的再次血运重建)发生率和支架内血栓发生率。结果:120例急性心肌梗死患者靶血管共植入支架152枚,术后即刻TIMI3级获得率95.8%,住院期间死亡1例。术后6个月临床随访总MACE事件的发生率为5%,死亡2例,靶血管的再次血运重建4例,无再发心梗和支架内血栓发生。结论:国产西罗莫司洗脱支架Firebird2TM对急性心肌梗死患者具有良好的安全性和疗效。
Objective: To evaluate the safety and efficacy of domestic-made sirolimus-eluting stent Firebird2TM in the treatment of acute myocardial infarction. Methods: A total of 120 consecutive patients with acute myocardial infarction in our hospital from September 2010 to December 2011 were selected. All patients underwent coronary angiography of target vessel characteristics, stent placement, major cardiac adverse events at 6 months after hospitalization and at stent implantation (MACE, including death, recurrent MI, target revascularization Reconstruction) and incidence of stent thrombosis. Results: A total of 152 stents were implanted in 120 patients with acute myocardial infarction. The TIMI3 grade was 95.8% immediately after operation and 1 patient died during hospitalization. At 6 months postoperatively, the overall incidence of MACE events was 5%, with 2 deaths and 4 revascularization of target vessels. There was no recurrence of myocardial infarction and stent thrombosis. Conclusion: Domestic sirolimus-eluting stent Firebird2TM has good safety and efficacy in patients with acute myocardial infarction.